# Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes

> **NCT02808351** · PHASE4 · COMPLETED · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 800 (actual)

## Conditions studied

- Diabetes Mellitus
- Chronic Kidney Disease

## Interventions

- **DRUG:** Berberine

## Key facts

- **NCT ID:** NCT02808351
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 800 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808351, "Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT02808351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*